Whole Exome Sequencing Services

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive boulevard, EPS, Suite 600, Room 6070, Rockville, MD 20852, UNITED STATES Description The National Cancer Institute (NCI), Center for Cancer Research (CCR), Neuro-Oncology Branch (NOB) plans to procure on a sole source basis services from Ambry Genetics, 100 Columbia #200, Aliso Viejo, CA 92656 to perform Agilent SureSelect Human Whole Exome 50MB target enrichment testing of samples from cases and controls. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System code is 541380 and the business size standard is $12.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance shall be for twelve months from date of award. It has been determined that there is no opportunity to acquire green products or services under this contract. The Center for Cancer Research (CCR), Neuro-Oncology Branch (NOB) is working to develop new therapies for patients with primary brain and spinal cord tumors. The NOB has been intensively studying glioblastoma and has been highly interested in characterizing the genomic alterations that underlie this disease in order to find targets for therapy. Through the advent of new technologies that will allow the sequencing of the entire exome, the NOB is now able to find mutations within regions that are potentially the most important, which are protein-coding regions. The purpose of this procurement is to perform Exome sequencing of 32 human samples and quality controls using the Agilent SureSelect 50 MB enrichment system, library preparation, indexing, and 100bp paired end processing using the Illumina HiSeq2000 system. Ambry Genetics is the only known laboratory that is both a certified Agilent SureSelect Certified Service Provider and Illumina Certified Service Provider. Ambry will use the Agilent SureSelect 50MB enrichment system, library preparation, indexing, and perform the 100bp paired end sequencing using the Illumina HiSeq2000 system, and hence be able to deliver the type of data compatible with the data already generated in the NOB. The purchase is needed to continue an on-going experiment, and a change would be disruptive to current experiments. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on June 14, 2012. No electronic capability statements will be accepted (i.e. email or FAX), and original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301- 402-4513) or emailed to Laura Glockner, Contract Specialist at contact@example.gov. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov . No collect calls will be accepted. Please reference solicitation number NCI-120075-LG on all correspondence.